Proficiency of phenotypic drug susceptibility testing for Mycobacterium tuberculosis in China, 2008-2021

• Published in: PloS one Vol. 19; no. 5; p. e0304265
• Main Authors: Song, Yuanyuan, Zhao, Bing, Wang, Shengfen, Zheng, Yang, Zhou, Yang, Ou, Xichao, Xia, Hui, Zhao, Yanlin
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 29.05.2024; Public Library of Science (PLoS)
• Subjects: Amikacin; Amikacin - pharmacology; Amikacin - therapeutic use; Antitubercular Agents - pharmacology; Antitubercular Agents - therapeutic use; Biology and Life Sciences; Capreomycin; China; Data analysis; Drug therapy; Drugs; Humans; Kanamycin; Laboratories; Laboratory Proficiency Testing; Medicine and Health Sciences; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; Phenotype; Pyrazinamide; Pyrazinamide - therapeutic use; Reproducibility; Reproducibility of Results; Research and Analysis Methods; Sensitivity; Tuberculosis; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0304265

To analyze the results of proficiency testing for anti-tuberculosis drug susceptibility testing (DST) in China. Number of laboratory participating the proficiency testing performed DST, and the sensitivity, specificity, reproducibility, and accordance rate were calculated from data of 13 rounds proficiency testing results for DST from 2008 to 2021. A total of 30 and 20 strains of Mycobacterium tuberculosis with known susceptibility results were sent to each laboratory in 2008 to 2019, 2020 and 2021, respectively. The number of participating laboratories ranged from 30 in 2009 to 546 in 2021. L-J DST was the predominant method. The specificity presented relatively higher than sensitivity. Improvement of specificity were observed for all drugs through the years, while sensitivity did not show improvement for amikacin and capreomycin. Accordance rate of pyrazinamide and kanamycin and reproducibility of capreomycin and pyrazinamide were not significantly improved through the years. Most of the participating laboratories significantly improved the quality of their DST through the consecutive rounds of proficiency testing except for second-line injectable drugs and pyrazinamide. The results highlight the importance of developing novel and/or improving existing methods for phenotypic DST for certain drugs.